Related Experiment Video
Updated: May 6, 2026
08:17
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
15.2K
Secondary neoplasms after stereotactic radiosurgery
Toral R Patel1, Veronica L S Chiang1
1Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut, USA.
World Neurosurgery
|October 24, 2013
Summary
The risk of developing secondary neoplasms after stereotactic radiosurgery (SRS) is low, approximately 0.04% at 15 years. Continued surveillance imaging is recommended for patients undergoing SRS treatment.
Area of Science:
- Neurosurgery
- Radiation Oncology
- Oncology
Background:
- Medical radiation use has surged sixfold in 30 years.
- Stereotactic radiosurgery (SRS) has transformed central nervous system disease treatment.
- Long-term risks of SRS, like secondary neoplasms, require further study.
Purpose of the Study:
- To assess the risk of secondary neoplasms following SRS.
- To consolidate existing data on radiation-induced tumors post-SRS.
Main Methods:
- Systematic review of published literature.
- Identification and analysis of reported cases of SRS-induced neoplasms.
Main Results:
- 36 cases of SRS-induced neoplasms were identified.
- Vestibular schwannoma was the most common initial diagnosis.
- The estimated risk of developing an SRS-induced neoplasm is 0.04% at 15 years.
Conclusions:
- The risk of secondary neoplasms after SRS is low but present.
- Long-term surveillance imaging is advised for patients treated with SRS.
